Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy
$267m Deal Expands Biotech’s Research
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
You may also be interested in...
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
AstraZeneca's CEO and other leaders from COVID-19 vaccine companies will face some tough questions in Brussels, but the European Commission wants to put differences behind it and solve the vaccine supply problem as soon as possible.
Observational studies from the National Health Service show encouraging signs for the UK’s vaccination program.